Business Description
Schott Pharma AG & CO KGaA
ISIN : DE000A3ENQ51
Description
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.42 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.28 | |||||
| Interest Coverage | 14.04 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 5.27 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.4 | |||||
| 3-Year EBITDA Growth Rate | 23.2 | |||||
| 3-Year EPS without NRI Growth Rate | 23.9 | |||||
| 3-Year FCF Growth Rate | -31.4 | |||||
| 3-Year Book Growth Rate | 30 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 12.29 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.45 | |||||
| 9-Day RSI | 50.08 | |||||
| 14-Day RSI | 45.35 | |||||
| 6-1 Month Momentum % | 11.84 | |||||
| 12-1 Month Momentum % | 12.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.41 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.07 | |||||
| Days Inventory | 83.38 | |||||
| Days Sales Outstanding | 63.14 | |||||
| Days Payable | 48.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.54 | |||||
| Dividend Payout Ratio | 0.15 | |||||
| Forward Dividend Yield % | 0.54 | |||||
| 5-Year Yield-on-Cost % | 0.54 | |||||
| Shareholder Yield % | 0.61 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 34.18 | |||||
| Operating Margin % | 17.07 | |||||
| Net Margin % | 15.86 | |||||
| FCF Margin % | 2.27 | |||||
| ROE % | 21.17 | |||||
| ROA % | 11.78 | |||||
| ROIC % | 14.13 | |||||
| ROC (Joel Greenblatt) % | 28.54 | |||||
| ROCE % | 20.2 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.48 | |||||
| Forward PE Ratio | 24.03 | |||||
| PE Ratio without NRI | 26.48 | |||||
| PS Ratio | 4.2 | |||||
| PB Ratio | 5.2 | |||||
| Price-to-Tangible-Book | 5.64 | |||||
| Price-to-Free-Cash-Flow | 187.8 | |||||
| Price-to-Operating-Cash-Flow | 20.9 | |||||
| EV-to-EBIT | 22.61 | |||||
| EV-to-EBITDA | 16.67 | |||||
| EV-to-Revenue | 4.43 | |||||
| EV-to-FCF | 197.81 | |||||
| Price-to-Graham-Number | 2.63 | |||||
| Earnings Yield (Greenblatt) % | 4.42 | |||||
| FCF Yield % | 0.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Schott Pharma AG & CO KGaA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 948.556 | ||
| EPS (TTM) (€) | 1 | ||
| Beta | 0 | ||
| Volatility % | 41.72 | ||
| 14-Day RSI | 45.35 | ||
| 14-Day ATR (€) | 1.029727 | ||
| 20-Day SMA (€) | 27.67 | ||
| 12-1 Month Momentum % | 12.39 | ||
| 52-Week Range (€) | 25.54 - 43.4 | ||
| Shares Outstanding (Mil) | 150.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Schott Pharma AG & CO KGaA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Schott Pharma AG & CO KGaA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Schott Pharma AG & CO KGaA Frequently Asked Questions
What is Schott Pharma AG & CO KGaA(XTER:1SXP)'s stock price today?
The current price of XTER:1SXP is €27.60. The 52 week high of XTER:1SXP is €43.40 and 52 week low is €25.54.
When is next earnings date of Schott Pharma AG & CO KGaA(XTER:1SXP)?
The next earnings date of Schott Pharma AG & CO KGaA(XTER:1SXP) is .
Does Schott Pharma AG & CO KGaA(XTER:1SXP) pay dividends? If so, how much?
The Dividend Yield %  of Schott Pharma AG & CO KGaA(XTER:1SXP) is 0.54% (As of Today), Highest Dividend Payout Ratio of Schott Pharma AG & CO KGaA(XTER:1SXP) was 0.15. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Schott Pharma AG & CO KGaA(XTER:1SXP) is 0.54%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers